Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Evaluate immunogenicity and safety of recombinant human papillomavirus bivalent ( types 16 and 18 ) vaccine ( Yeast )in different age group. And evaluate persistence of immune response in 9-17years age group. To demonstrate that 9-17years age group was non-inferior to 18-26 years age group and 27-45 years age group in terms of immunogenicity.
Epistemonikos ID: 991829fd24bd866e47b11055ee94196db1b4b082
First added on: May 12, 2024